We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 601 to 625
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 October 2017
-
Meeting statementsAdvisory Committee on Complementary Medicines Meeting 17 meeting statement
-
Meeting statementsACMD 31 meeting statement has been published
-
Meeting statementsACM 1 meeting statement has been published
-
Corporate reportsTGA Stakeholder Survey 2016-17 - questions and answers
-
Scheduling decisions (final)Final decisions for medicines and chemicals referred to March 2017 scheduling meetings (ACMS #20, ACCS #19 and Joint ACMS-ACCS #15) and NCEs.
-
Corporate reportsSummary of generic and biosimilar prescription medicines registered in Australia in 2016
-
Scheduling decisions (final)New Chemical Entity (NCE) delegate's final decision and reasons for decision for brexpiprazole
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 31 May 2017
-
Meeting statementsACMD meeting statement, Meeting 25, 26 February 2016
-
Meeting statementsACMD meeting statement, Meeting 26, 29 April 2016
-
Meeting statementsACMD meeting statement, Meeting 27, 24 June 2016
-
Meeting statementsACMD meeting statement, Meeting 28, 26 August 2016
-
Meeting statementsACMD meeting statement, Meeting 29, 21 October 2016
-
Meeting statementsACMD meeting statement, Meeting 30, 2 December 2016
-
Meeting statementsAdvisory Committee on Medical Devices, Meeting 23 statement
-
Meeting statementsAdvisory Committee on Medical Devices, Meeting 24 statement
-
Scheduling decisions (final)Delegate-only final decisions to amend the Poisons Standard not referred to an expert advisory committee.
-
Corporate reportsThe TGA's scientific review on the safety of nanoparticles in sunscreens.
-
Corporate reportsEconomic modelling and financial quantification of the regulatory impact of proposed changes to codeine scheduling
-
Corporate reportsRegulation impact statement: Codeine re-scheduling
-
Scheduling decisions (final)Q&A about changes to the scheduling of codeine.
-
Meeting statementsThe TGC 42 meeting statement has now been published
-
Corporate reportsRegulation impact statement: General requirements for labels for medicines
-
Meeting statementsAdvisory Committee on Prescription Medicines, meeting statement